538 Bath-PUVA therapy changes inflammatory profiles for systemic effects beyond the skin

Psoriasis is a cutaneous disease as well systemic chronic inflammatory that closely associated with multiple comorbidities, such cardiovascular diseases, diabetes, and metabolic syndrome. Recently developed treatment modalities are highly effective for psoriasis skin lesions. The greater the extent of body surface area affected, more prone patient to psoriatic arthritis inflammation. Therefore, tight control lesions may reduce incidence future comorbidities. Bath-psoralen plus ultraviolet A (PUVA) well-established phototherapy psoriasis. This study aimed clarify effects bath-PUVA therapy by investigating changes in inflammatory- cardiovascular-associated protein levels. Using high-throughput proteomic assay (Olink Proteomics, Uppsala, Sweden), we performed comprehensive analysis 92 serum proteins before after 20 patients first treated between 2007 2011 our hospital. median PASI score was 23.8 (range 5.6–69.3); 90% achieved 75, 50% 90, 5% 100. reduction rates were similar those induced biologics. Nine positively correlated pre-treatment scores (r > 0.4). While CCL17 = 0.567) reported previously, other 8 have not been reported. Furthermore, detected 38 differentially expressed bath PUVA therapy, including CCL17, TNFRSF11A, PRSS27, HO-1, IL-18. We also functional enrichment Metascape gene sets coding these proteins. “cytokine-cytokine receptor interaction”, “inflammatory response”, “lipid atherosclerosis” process/pathway significantly changed treatment. Bath-PUVA might beyond skin, improving inflammation risk.